These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12685832)

  • 1. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
    Chua SL; Seymour JF; Streater J; Wolf MM; Januszewicz EH; Prince HM
    Leuk Lymphoma; 2002 Sep; 43(9):1783-8. PubMed ID: 12685832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
    Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
    Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary central nervous system lymphoma: risk factors and prophylaxis.
    Montoto S; Lister TA
    Hematol Oncol Clin North Am; 2005 Aug; 19(4):751-63, viii. PubMed ID: 16083835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.
    Haioun C; Besson C; Lepage E; Thieblemont C; Simon D; Rose C; Tilly H; Sonet A; Lederlin P; Attal M; Brière J; Reyes F
    Ann Oncol; 2000 Jun; 11(6):685-90. PubMed ID: 10942056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
    Bokstein F; Lossos A; Lossos IS; Siegal T
    Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system disease in hematologic malignancies: historical perspective and practical applications.
    Pui CH; Thiel E
    Semin Oncol; 2009 Aug; 36(4 Suppl 2):S2-S16. PubMed ID: 19660680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system involvement in T-cell lymphoma: A single center experience.
    Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
    Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.
    Hollender A; Kvaloy S; Nome O; Skovlund E; Lote K; Holte H
    Ann Oncol; 2002 Jul; 13(7):1099-107. PubMed ID: 12176790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature.
    Buckstein R; Lim W; Franssen E; Imrie KL
    Leuk Lymphoma; 2003 Jun; 44(6):955-62. PubMed ID: 12854893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group.
    Bos GM; van Putten WL; van der Holt B; van den Bent M; Verdonck LF; Hagenbeek A
    Ann Oncol; 1998 Feb; 9(2):191-4. PubMed ID: 9553665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neuropathologic evaluation of intrathecal prophylaxis results in adults with high grade non-Hodgkin's lymphomas].
    Zyluk B
    Ann Acad Med Stetin; 1997; 43():193-209. PubMed ID: 9471916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK.
    Cheung CW; Burton C; Smith P; Linch DC; Hoskin PJ; Ardeshna KM
    Br J Haematol; 2005 Oct; 131(2):193-200. PubMed ID: 16197449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma.
    Lim HY; Thiel E; Glantz MJ
    Curr Opin Oncol; 2008 Sep; 20(5):495-501. PubMed ID: 19106650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain.
    Sancho JM; Morgades M; Alonso N; Deben G; Fernández de Sevilla A; Vázquez L; Nicolás C; García Vela JA; Arranz R; Abella E; Canales MA; Miralles P; Sánchez E; Hermosilla M; Conde E; Rueda A; Ribera JM;
    Med Clin (Barc); 2008 Oct; 131(12):441-6. PubMed ID: 18928733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
    Korfel A; Thiel E
    Leuk Lymphoma; 1998 Aug; 30(5-6):609-17. PubMed ID: 9711923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.
    Herrlinger U; Glantz M; Schlegel U; Gisselbrecht C; Cavalli F
    Semin Oncol; 2009 Aug; 36(4 Suppl 2):S25-34. PubMed ID: 19660681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience.
    Pectasides D; Economopoulos T; Kouvatseas G; Antoniou A; Zoumbos Z; Aravantinos G; Tsatalas C; Halikia A; Nikolaides C; Kiamouris C; Pappa E; Pavlidis N; Skarlos D; Fountzilas G; Dimopoulos MA
    Oncology; 2000 May; 58(4):286-92. PubMed ID: 10838493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.